메뉴 건너뛰기




Volumn 30, Issue 9, 2014, Pages 896-906

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL RESISTANCE; CROSS-SECTIONAL STUDY; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; UGANDA;

EID: 84906919930     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0043     Document Type: Article
Times cited : (27)

References (55)
  • 1
    • 40949107410 scopus 로고    scopus 로고
    • Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    • Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer W, Shikuma C, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008;197:867-870.
    • (2008) J Infect Dis , vol.197 , pp. 867-870
    • Kuritzkes, D.R.1    Lalama, C.M.2    Ribaudo, H.J.3    Marcial, M.4    Meyer, W.5    Shikuma, C.6
  • 2
    • 79955477986 scopus 로고    scopus 로고
    • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study
    • Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011;11:363-371.
    • (2011) Lancet Infect Dis , vol.11 , pp. 363-371
    • Wittkop, L.1    Günthard, H.F.2    De Wolf, F.3    Dunn, D.4    Cozzi-Lepri, A.5    De Luca, A.6
  • 4
    • 0037055016 scopus 로고    scopus 로고
    • Time trends in primary HIV-1 drug resistance among recently infected persons
    • Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
    • (2002) JAMA , vol.288 , pp. 181-188
    • Grant, R.M.1    Hecht, F.M.2    Warmerdam, M.3    Liu, L.4    Liegler, T.5    Petropoulos, C.J.6
  • 5
    • 83755225761 scopus 로고    scopus 로고
    • British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
    • Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, et al.: British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012;13:1-44.
    • (2012) HIV Med , vol.13 , pp. 1-44
    • Asboe, D.1    Aitken, C.2    Boffito, M.3    Booth, C.4    Cane, P.5    Fakoya, A.6
  • 7
    • 84864131448 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel
    • Thompson MA, Aberg JA, Hoy JF, Benson C, Gu HF, Hammer SM, et al.: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. J Am Med Assoc 2012;308: 387-402.
    • (2012) J Am Med Assoc , vol.308 , pp. 387-402
    • Thompson, M.A.1    Aberg, J.A.2    Hoy, J.F.3    Benson, C.4    Gu, H.F.5    Hammer, S.M.6
  • 10
    • 70149095523 scopus 로고    scopus 로고
    • Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
    • Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al.: Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-681.
    • (2009) Clin Infect Dis , vol.49 , pp. 651-681
    • Aberg, J.A.1    Kaplan, J.E.2    Libman, H.3    Emmanuel, P.4    Anderson, J.R.5    Stone, V.E.6
  • 11
    • 67649188260 scopus 로고    scopus 로고
    • Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries
    • Aghokeng AF, Vergne L, Mpoudi-ngole E, Mbangue M, and Deoudje N: Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009;14: 401-411.
    • (2009) Antivir Ther , vol.14 , pp. 401-411
    • Aghokeng, A.F.1    Vergne, L.2    Mpoudi-Ngole, E.3    Mbangue, M.4    Deoudje, N.5
  • 12
    • 79953763329 scopus 로고    scopus 로고
    • Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam Tanzania
    • Mosha F, Urassa W, Aboud S, Lyamuya E, Sandstrom E, Bredell H, et al.: Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2011;27:377-382.
    • (2011) AIDS Res Hum Retroviruses , vol.27 , pp. 377-382
    • Mosha, F.1    Urassa, W.2    Aboud, S.3    Lyamuya, E.4    Sandstrom, E.5    Bredell, H.6
  • 13
    • 33750524856 scopus 로고    scopus 로고
    • The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world
    • Bennett DE: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006;19:607-614.
    • (2006) Curr Opin Infect Dis , vol.19 , pp. 607-614
    • Bennett, D.E.1
  • 14
    • 38149109662 scopus 로고    scopus 로고
    • Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B
    • Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, et al.: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008;46:177-184.
    • (2008) J Clin Microbiol , vol.46 , pp. 177-184
    • Ndembi, N.1    Abraha, A.2    Pilch, H.3    Ichimura, H.4    Mbanya, D.5    Kaptue, L.6
  • 15
    • 33846025131 scopus 로고    scopus 로고
    • Epidemiology of antiretroviral drug resistance in drug-naive persons
    • Geretti AM: Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007; 20:22-32.
    • (2007) Curr Opin Infect Dis , vol.20 , pp. 22-32
    • Geretti, A.M.1
  • 16
    • 79954853192 scopus 로고    scopus 로고
    • Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala
    • Ndembi N, Hamers RL, Sigaloff KCE, Lyagoba F, Magambo B, Nanteza B, et al.: Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011;25: 905-910.
    • (2011) AIDS , vol.25 , pp. 905-910
    • Ndembi, N.1    Hamers, R.L.2    Sigaloff, K.C.E.3    Lyagoba, F.4    Magambo, B.5    Nanteza, B.6
  • 17
    • 84877998235 scopus 로고    scopus 로고
    • Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara Uganda
    • Kaida A, Matthews LT, Kanters S, Kabakyenga J, Muzoora C, Mocello R, et al.: Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One 2013;8: e63411.
    • (2013) PLoS One , vol.8
    • Kaida, A.1    Matthews, L.T.2    Kanters, S.3    Kabakyenga, J.4    Muzoora, C.5    Mocello, R.6
  • 19
    • 84862098342 scopus 로고    scopus 로고
    • Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool
    • Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al.: Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012;50:1936-1942.
    • (2012) J Clin Microbiol , vol.50 , pp. 1936-1942
    • Woods, C.K.1    Brumme, C.J.2    Liu, T.F.3    Chui, C.K.S.4    Chu, A.L.5    Wynhoven, B.6
  • 20
    • 62749200513 scopus 로고    scopus 로고
    • Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
    • Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
    • (2009) PLoS One , vol.4
    • Bennett, D.E.1    Camacho, R.J.2    Otelea, D.3    Kuritzkes, D.R.4    Fleury, H.5    Kiuchi, M.6
  • 21
    • 33748879209 scopus 로고    scopus 로고
    • Rationale and uses of a public HIV drugresistance database
    • Shafer RW: Rationale and uses of a public HIV drugresistance database. J Infect Dis 2006;194(Suppl): S51-58.
    • (2006) J Infect Dis , vol.194 , Issue.SUPPL.
    • Shafer, R.W.1
  • 23
    • 4744355003 scopus 로고    scopus 로고
    • Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection
    • Alexander CS, Montaner JSG, Asselin JJ, Ting L, McNabb K, Harris M, et al.: Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection. Ther Drug Monit 2004;26:516-523.
    • (2004) Ther Drug Monit , vol.26 , pp. 516-523
    • Alexander, C.S.1    Montaner, J.S.G.2    Asselin, J.J.3    Ting, L.4    McNabb, K.5    Harris, M.6
  • 24
    • 40549113345 scopus 로고    scopus 로고
    • HIV-1 subtype as a determinant of disease progression
    • Kuritzkes DR: HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008;197:638-639.
    • (2008) J Infect Dis , vol.197 , pp. 638-639
    • Kuritzkes, D.R.1
  • 25
    • 40549121269 scopus 로고    scopus 로고
    • Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection
    • Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197:707-713.
    • (2008) J Infect Dis , vol.197 , pp. 707-713
    • Kiwanuka, N.1    Laeyendecker, O.2    Robb, M.3    Kigozi, G.4    Arroyo, M.5    McCutchan, F.6
  • 26
    • 34047207715 scopus 로고    scopus 로고
    • HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads
    • Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al.: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180.
    • (2007) J Infect Dis , vol.195 , pp. 1177-1180
    • Baeten, J.M.1    Chohan, B.2    Lavreys, L.3    Chohan, V.4    McClelland, R.S.5    Certain, L.6
  • 27
    • 0035132179 scopus 로고    scopus 로고
    • The stability between two HIV-1 RNA measurements one year apart and the relationship with HIV subtype in rural Uganda
    • Morgan D, Kaleebu P, Whitworth J, Yirrell D, Rutebemberwa a., Shier R, et al.: The stability between two HIV-1 RNA measurements one year apart and the relationship with HIV subtype in rural Uganda. Int J STD AIDS 2001;12:116-121.
    • (2001) Int J STD AIDS , vol.12 , pp. 116-121
    • Morgan, D.1    Kaleebu, P.2    Whitworth, J.3    Yirrell, D.4    Rutebemberwa, A.5    Shier, R.6
  • 28
    • 84906915612 scopus 로고    scopus 로고
    • World Health Organization Accessed May 27, 2013
    • World Health Organization: Surveillance of transmitted HIV drug resistance. 2013. www.who.int/hiv/topics/drug resistance/surveillance/en/index. html. Accessed May 27, 2013.
    • (2013) Surveillance of Transmitted HIV Drug Resistance
  • 29
    • 84858988089 scopus 로고    scopus 로고
    • Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world
    • Frentz D, Boucher CA, van de Vijver DA, et al.: Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012;14: 17-27.
    • (2012) AIDS Rev , vol.14 , pp. 17-27
    • Frentz, D.1    Boucher, C.A.2    Van De Vijver, D.A.3
  • 30
    • 84878295758 scopus 로고    scopus 로고
    • World Health Organization Geneva, Switzerland
    • World Health Organization: The HIV drug resistance report-2012. Geneva, Switzerland, 2012.
    • (2012) The HIV Drug Resistance report-2012
  • 31
    • 84862515892 scopus 로고    scopus 로고
    • Uganda Ministry of Health Kampala, Uganda
    • Uganda Ministry of Health: Uganda Clinical Guidelines 2010. Kampala, Uganda, 2010.
    • (2010) Uganda Clinical Guidelines 2010
  • 32
    • 84866987811 scopus 로고    scopus 로고
    • Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients
    • Yanik EL, Napravnik S, Hurt CB, Dennis A, Quinlivan EB, Sebastian J, et al.: Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258-262.
    • (2012) J Acquir Immune Defic Syndr , vol.61 , pp. 258-262
    • Yanik, E.L.1    Napravnik, S.2    Hurt, C.B.3    Dennis, A.4    Quinlivan, E.B.5    Sebastian, J.6
  • 33
    • 76249130812 scopus 로고    scopus 로고
    • Evolutionary dynamics of complex networks of HIV drugresistant strains: The case of San Francisco
    • Smith RJ, Okano JT, Kahn JS, Bodine EN, and Blower S: Evolutionary dynamics of complex networks of HIV drugresistant strains: The case of San Francisco. Science 2010; 327:697-701.
    • (2010) Science , vol.327 , pp. 697-701
    • Smith, R.J.1    Okano, J.T.2    Kahn, J.S.3    Bodine, E.N.4    Blower, S.5
  • 34
    • 84867079060 scopus 로고    scopus 로고
    • Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis
    • Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, et al.: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet 2012;380:1250-1258.
    • (2012) Lancet , vol.380 , pp. 1250-1258
    • Gupta, R.K.1    Jordan, M.R.2    Sultan, B.J.3    Hill, A.4    Davis, D.H.J.5    Gregson, J.6
  • 35
    • 3042817611 scopus 로고    scopus 로고
    • Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission
    • Delaugerre C, Morand-Joubert L, Chaix M-L, Picard O, Marcelin A-G, Schneider V, et al.: Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004;9:415-421.
    • (2004) Antivir Ther , vol.9 , pp. 415-421
    • Delaugerre, C.1    Morand-Joubert, L.2    Chaix, M.-L.3    Picard, O.4    Marcelin, A.-G.5    Schneider, V.6
  • 37
    • 33646017725 scopus 로고    scopus 로고
    • HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time
    • Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard J-P, Galimand J, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159-170.
    • (2006) AIDS , vol.20 , pp. 159-170
    • Ghosn, J.1    Pellegrin, I.2    Goujard, C.3    Deveau, C.4    Viard, J.-P.5    Galimand, J.6
  • 38
    • 33645534025 scopus 로고    scopus 로고
    • Evolution of transmitted HIV-1 with drugresistance mutations in the absence of therapy: Effects on CD4 + T-cell count and HIV-1 RNA load
    • Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, et al.: Evolution of transmitted HIV-1 with drugresistance mutations in the absence of therapy: Effects on CD4 + T-cell count and HIV-1 RNA load. Antivir Ther 2006;11:173-178.
    • (2006) Antivir Ther , vol.11 , pp. 173-178
    • Bezemer, D.1    De Ronde, A.2    Prins, M.3    Porter, K.4    Gifford, R.5    Pillay, D.6
  • 39
    • 4143113433 scopus 로고    scopus 로고
    • Persistence of primary drug resistance among recently HIV-1 infected adults
    • Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead C a, Busch MP, et al.: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18: 1683-1689.
    • (2004) AIDS , vol.18 , pp. 1683-1689
    • Barbour, J.D.1    Hecht, F.M.2    Wrin, T.3    Liegler, T.J.4    Ramstead, C.A.5    Busch, M.P.6
  • 40
    • 4143093674 scopus 로고    scopus 로고
    • Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection
    • Brenner B, Routy J-P, Quan Y, Moisi D, Oliveira M, Turner D, et al.: Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004;18:1653-1660.
    • (2004) AIDS , vol.18 , pp. 1653-1660
    • Brenner, B.1    Routy, J.-P.2    Quan, Y.3    Moisi, D.4    Oliveira, M.5    Turner, D.6
  • 41
    • 0347479194 scopus 로고    scopus 로고
    • Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    • Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, et al.: Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37:1693-1698.
    • (2003) Clin Infect Dis , vol.37 , pp. 1693-1698
    • Gandhi, R.T.1    Wurcel, A.2    Rosenberg, E.S.3    Johnston, M.N.4    Hellmann, N.5    Bates, M.6
  • 42
    • 0035037383 scopus 로고    scopus 로고
    • Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy
    • Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, et al.: Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008.
    • (2001) J Virol , vol.75 , pp. 4999-5008
    • Bacheler, L.1    Jeffrey, S.2    Hanna, G.3    D'Aquila, R.4    Wallace, L.5    Logue, K.6
  • 43
    • 0002693981 scopus 로고    scopus 로고
    • Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility
    • Huang W, Limoli K, Sartoris K, et al.: Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility. Antiviral Ther 1999;4(Suppl 1): 50-51.
    • (1999) Antiviral Ther , vol.4 , Issue.SUPPL. 1 , pp. 50-51
    • Huang, W.1    Limoli, K.2    Sartoris, K.3
  • 44
    • 0031805095 scopus 로고    scopus 로고
    • S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type
    • Fujiwara T, Sato A, El-farrash M, Abe K, Isaka Y, Kodama M, et al.: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type. Antimicrob Agents Chemother 1998;42:1340-1345.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 1340-1345
    • Fujiwara, T.1    Sato, A.2    El-Farrash, M.3    Abe, K.4    Isaka, Y.5    Kodama, M.6
  • 45
    • 0027231438 scopus 로고
    • A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
    • Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, et al.: A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90:4713-4717.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 4713-4717
    • Dueweke, T.J.1    Pushkarskaya, T.2    Poppe, S.M.3    Swaney, S.M.4    Zhao, J.Q.5    Chen, I.S.6
  • 46
    • 34247583029 scopus 로고    scopus 로고
    • Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes
    • Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, and Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146(8):564-573.
    • (2007) Ann Intern Med , vol.146 , Issue.8 , pp. 564-573
    • Nachega, J.B.1    Hislop, M.2    Dowdy, D.W.3    Chaisson, R.E.4    Regensberg, L.5    Maartens, G.6
  • 47
    • 0034604276 scopus 로고    scopus 로고
    • Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
    • Paterson DL, Swindells S, Mohr J, Brester M, and Vergis EN: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1):21-30.
    • (2000) Ann Intern Med , vol.133 , Issue.1 , pp. 21-30
    • Paterson, D.L.1    Swindells, S.2    Mohr, J.3    Brester, M.4    Vergis, E.N.5
  • 48
    • 48749086685 scopus 로고    scopus 로고
    • Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-näve populations and associate with reduced treatment efficacy
    • Johnson J A, Li J-F, Wei X, Lipscomb J, Irlbeck D, Craig C, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-näve populations and associate with reduced treatment efficacy. PLoS Med 2008;5: e158.
    • (2008) PLoS Med , vol.5
    • Johnson, J.A.1    Li, J.-F.2    Wei, X.3    Lipscomb, J.4    Irlbeck, D.5    Craig, C.6
  • 49
    • 77954192930 scopus 로고    scopus 로고
    • Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution
    • Johnson J and Geretti AM: Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 2010; 65:1322-1326.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 1322-1326
    • Johnson, J.1    Geretti, A.M.2
  • 50
    • 76449101531 scopus 로고    scopus 로고
    • Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
    • Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, et al.: Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010;201: 662-671.
    • (2010) J Infect Dis , vol.201 , pp. 662-671
    • Paredes, R.1    Lalama, C.M.2    Ribaudo, H.J.3    Schackman, B.R.4    Shikuma, C.5    Giguel, F.6
  • 51
    • 61849172898 scopus 로고    scopus 로고
    • Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatmentnaive patients significantly impact treatment outcomes
    • Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatmentnaive patients significantly impact treatment outcomes. J Infect Dis 2009;199:693-701.
    • (2009) J Infect Dis , vol.199 , pp. 693-701
    • Simen, B.B.1    Simons, J.F.2    Hullsiek, K.H.3    Novak, R.M.4    MacArthur, R.D.5    Baxter, J.D.6
  • 52
    • 79953745195 scopus 로고    scopus 로고
    • Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis
    • Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305:1327-1335.
    • (2011) JAMA , vol.305 , pp. 1327-1335
    • Li, J.Z.1    Paredes, R.2    Ribaudo, H.J.3    Svarovskaia, E.S.4    Metzner, K.J.5    Kozal, M.J.6
  • 53
    • 73349116621 scopus 로고    scopus 로고
    • Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy
    • Geretti AM, Fox Z V, Booth CL, Smith CJ, Phillips AN, Johnson M, et al.: Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:569-573.
    • (2009) J Acquir Immune Defic Syndr , vol.52 , pp. 569-573
    • Geretti, A.M.1    Fox, Z.V.2    Booth, C.L.3    Smith, C.J.4    Phillips, A.N.5    Johnson, M.6
  • 54
    • 65549129096 scopus 로고    scopus 로고
    • Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy
    • Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009;48:1296-1305.
    • (2009) Clin Infect Dis , vol.48 , pp. 1296-1305
    • Geretti, A.M.1    Harrison, L.2    Green, H.3    Sabin, C.4    Hill, T.5    Fearnhill, E.6
  • 55
    • 84857656362 scopus 로고    scopus 로고
    • Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy
    • Franzetti M, Violin M, Casazza G, Meini G, Callegaro A, Corsi P, et al.: Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. Clin Microbiol Infect 2012;18:E66-70.
    • (2012) Clin Microbiol Infect , vol.18
    • Franzetti, M.1    Violin, M.2    Casazza, G.3    Meini, G.4    Callegaro, A.5    Corsi, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.